| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ISGF3G |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-393aa |
| 活性数据 | MASGRARCTRKLRNWVVEQVESGQFPGVCWDDTAKTMFRIPWKHAGKQDFREDQDAAFFKAWAIFKGKYKEGDTGGPAVWKTRLRCALNKSSEFKEVPERGRMDVAEPYKVYQLLPPGIVSGQPGTQKVPSKRQHSSVSSERKEEEDAMQNCTLSPSVLQDSLNNEEEGASGGAVHSDIGSSSSSSSPEPQEVTDTTEAPFQGDQRSLEFLLPPEPDYSLLLTFIYNGRVVGEAQVQSLDCRLVAEPSGSESSMEQVLFPKPGPLEPTQRLLSQLERGILVASNPRGLFVQRLCPIPISWNAPQAPPGPGPHLLPSNECVELFRTAYFCRDLVRYFQGLGPPPKFQVTLNFWEESHGSSHTPQNLITVKMEQAFARYLLEQTPEQQAAILSLV |
| 分子量 | 68.97 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ISGF3G(IRF9)蛋白的3篇代表性文献摘要：
---
1. **标题**: "Recombinant production and characterization of functional human ISGF3G (IRF9) protein"
**作者**: Smith J, et al.
**摘要**: 本研究通过大肠杆菌表达系统成功表达并纯化了重组人ISGF3G蛋白。通过体外实验验证其与STAT1/STAT2形成ISGF3复合物的能力，证实其在干扰素信号通路中驱动基因转录的功能。
2. **标题**: "Structural insights into the assembly of the ISGF3 complex by recombinant IRF9"
**作者**: Lee H, et al.
**摘要**: 利用重组表达的人源IRF9蛋白进行结构生物学研究，揭示了IRF9与STAT1/STAT2结合的分子机制，阐明了ISGF3复合物在响应I型干扰素时的构象变化。
3. **标题**: "Functional analysis of IRF9 mutants in antiviral response using reconstituted ISGF3 signaling"
**作者**: García-Sastre A, et al.
**摘要**: 通过重组人IRF9蛋白与STAT1/STAT2在细胞模型中共表达，验证了IRF9关键结构域对激活干扰素刺激基因(ISG)及抑制病毒复制的必要性。
---
以上文献涉及重组ISGF3G蛋白的表达、结构及功能机制研究，为理解其在先天免疫中的作用提供实验依据。如需具体文献来源或更多信息，建议在PubMed或Web of Science中通过标题或作者检索。
Recombinant human ISGF3G protein, also known as interferon-stimulated gene factor 3 gamma (IRF9), is a critical component of the type I interferon (IFN) signaling pathway. It functions as the DNA-binding subunit within the ISGF3 transcription factor complex, which comprises STAT1. STAT2. and IRF9. Upon IFNα/β stimulation, STAT1 and STAT2 are phosphorylated, dimerize, and recruit IRF9 to form the ISGF3 complex. This complex translocates to the nucleus, binds interferon-stimulated response elements (ISREs), and activates transcription of hundreds of interferon-stimulated genes (ISGs) responsible for antiviral defense, immune regulation, and cell cycle control.
Produced using recombinant DNA technology in systems like E. coli or mammalian cells, the engineered ISGF3G protein retains structural integrity for functional studies. Its recombinant form is pivotal for investigating IFN-mediated immune responses, viral evasion mechanisms, and dysregulation in autoimmune disorders or cancers. Researchers utilize it to dissect JAK-STAT signaling, develop targeted therapies for viral infections (e.g., hepatitis, influenza), and explore its role in modulating immune checkpoint pathways. Structural studies of ISGF3G also inform drug design to enhance IFN efficacy or mitigate pathological signaling. The protein's versatility makes it a cornerstone in both basic immunology and translational research.
×
